Skip to main content

Table 3 Tumor response and median survival after 90Y-RE in HCC patients

From: Minimally invasive image-guided therapy for inoperable hepatocellular carcinoma: What is the evidence today?

Study Patients (n) Tumor response on CTa Median survival (months) Microspheres
   CR (%) PR (%) SD (%) PD (%)   
Lau et al. (1998)[142] 71 0 27 65 8 9.4 Resin
Dancey et al. (2000) [143] 20 (19 evaluated for response) 5 16 58 21 12.5 Glass
Carr et al. (2004)[144] 65 NR 38 NR NR Okuda I: 21.3, Okuda II: 9.9 Glass
Geschwind et al. (2004)[145] 80 NR NR NR NR Okuda I: 20.6, Okuda II: 12.6 Glass
Goin (2005)[146] 121 NR NR NR NR Low risk: 15.3, high risk: 3.5 Glass
Salem (2005)[147] 43 NR 47 (79b) NR NR Okuda I: 24.4, Okuda II: 12.5 Glass
Sangro (2006)[148] 24 (21 evaluated for response) NR 88c (PR + SD) NR 7 Resin
Young (2007)[149] 41 NR NR NR NR Okuda I: 21.7, Okuda II: 14.2 Glass
Kulik (2008)[150] 108 NR 42.2 (70b) 34.7 23.1 No PVT: 15.4, branch PVT: 10.0, main PVT: 4.4 Glass
  1. Data of studies including ≥20 patients
  2. CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease
  3. PVT = portal vein thrombosis, NR = not reported
  4. aWHO criteria unless otherwise explained
  5. bEASL modified WHO criteria[151]
  6. cRECIST criteria[152]